CDH1 and head and neck squamous cell carcinoma: Our results consistently showed that the expression levels of the epithelial marker E-Cadherin increased upon treatment with dasatinib and saracatinib, while the expression of mesenchymal markers such as Vimentin and Snail decreased, thereby indicating that both compounds inhibit EMT in these two HNSCC cell lines (Supplementary Figure S4).